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1078–5884/00The Brachial Artery-basilic Vein Arterio-venous Fistula
in Vascular Access for Haemodialysis—A Review Paper
F.P. Dix,* Y. Khan and H. Al-KhaffafDepartment of Vascular Surgery, Burnley General Hospital, Burnley, Lancashire, UKAims. To review the available literature regarding patency rates and complications of the brachial-basilic arterio-venous
fistula (BBAVF) and to discuss this with relation to the current dialysis outcomes quality initiative guidelines.
Methods. An internet based literature search was performed using Pubmed, Medline and Medscape databases to identify all
published reports of the BBAVF in the English language from which the full articles were retrieved and cross-referenced.
Results. Of 136 papers identified, 28 were directly relevant to this review including four prospective studies (one
randomised trial, three non-randomised trials) and 24 retrospective studies. First described by Dagher in 1976, the BBAVF
has since been modified to a two-stage procedure with initial fistula formation followed by superficialisation of the basilic
vein 6 weeks later. It can be formed successfully in 95% of cases. Mean 1-year primary and secondary patency rates were 72
and 74.6%, respectively. Complications included haematoma (3.8%), stenosis (2.3%), thrombosis (9.7%), transient arm
oedema (3.7%), steal syndrome (2.9%) and aneurysm/pseudoaneurysm formation (1.9%). The BBAVF had a lower rate of
infection than prosthetic fistulas (3.6 vs. 16%).
Conclusions. The BBAVF has good primary and secondary patency rates with lower rates of infection than prosthetic
fistulas making it a preferred secondary access procedure.Keywords: Brachial-basilic fistula; Basilic vein transposition; Haemodialysis vascular access.Introduction
Haemodialysis was developed in 1944 as a successful
temporary treatment for patients with end stage renal
disease (ESRD) awaiting transplantation and in the
USA and Europe in 1999 there were 400,000 patients
maintained on haemodialysis.1,2 The success rate and
increased availability has considerably improved
patient long-term survival: more than 4000 patients
with ESRD required vascular access procedures in the
UK in 1989 and this number has now more than
doubled.3 The small number of available kidney
donors and the increased survival of patients means
that most will require a prolonged period of artificial
renal support necessitating the formation of an arterio-
venous fistula (AVF).ing author. F.P. Dix, Jr, Department of Vascular Surgery,
Hospital, Lancashire Teaching Hospitals NHS Trust,
Lane, Fulwood, Preston, Lancashire PR2 9HT, UK.
: francispauldix@aol.com
0070 + 10 $35.00/0 q 2005 Elsevier Ltd. All rights reserThe most commonly performed primary access
fistula is the radial-cephalic fistula first introduced in
1966 by Brescia with its relative ease of formation and
reliable patency rates.4 However, in a recent meta-
analysis there was a pooled primary failure rate of
15.3%, primary patency rate of only 62.5% and a
secondary patency rate of 66.0% at 1 year.5 Con-
troversy also exists regarding the best type of fistula to
be formed in secondary and tertiary access procedures
when primary fistulas have failed.
The brachial-basilic arterio-venous fistula (BBAVF)
was first described by Cascardo in 1970 and Dagher in
1976. With this technique, the basilic vein is anasto-
mosed to the brachial artery in the antecubital fossa
and later superficialised to make it amenable to needle
puncture. Advantages are that it produces a long
length of straight, superficial fistula with a high flow
rate. It involves the formation of only one vascular
anastomosis, maintains anatomic continuity with the
axillary vein, obviates the need for autologous,
prosthetic or heterografts and can be used whenEur J Vasc Endovasc Surg 31, 70–79 (2006)
doi:10.1016/j.ejvs.2005.08.008, available online at http://www.sciencedirect.com onved.
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veins in the arm, the basilic vein is naturally deep and
protected from damage caused by previous venepunc-
ture making it an ideal haemodialysis conduit but
necessitating superficialisation.
The use of an autogenous arterio-venous access for
chronic haemodialysis is recommended by the
national kidney foundation dialysis outcomes quality
initiative practice guidelines (NKF-DOQI).6,7 These
guidelines recommend the use wherever possible of
native autogenous fistulas over synthetic grafts to
improve patency and contain costs, providing ade-
quate flow rates, low rates of complications and fistula
longevity. These guidelines are exceptionally conser-
vative in recommending that only 50% of patients
should have formation of autogenous AVFs and many
centres now achieve rates of 90% or more. These
guidelines also recommend that the order of pre-
ference for AVF placement is the radial-cephalic
primary AVF followed by the secondary brachial-
cephalic AVF and, if either of these is not viable then
a secondary/tertiary fistula should be fashioned using
a synthetic material before proceeding if necessary to a
BBAVF.
The purpose of this paper, was to review the
available literature relating to the formation of the
BBAVF in terms of surgical technique, patency rates
and complications with particular reference to its use
as advocated by the DOQI guidelines.MethodsData sources
An internet based literature search was performed
using the words ‘basilic vein transposition’, ‘basilic
vein fistula’, ‘brachial-basilic fistula’ ‘brachial-basilic
arterio-venous fistula’ and ‘basilic vein elevation’. The
search included Pubmed, Medline and Medscape
databases to identify all published reports in the
English language. Manual cross-referencing from the
reference lists of all relevant articles identified further
papers included in this review.Outcome measures
The primary outcome measures were primary patency
and secondary patency rates. Primary patency rate
refers to the successful functioning of the fistula after
the initial procedure without further intervention.
Secondary patency rate refers to patency regardless of
the number of interventions.Statistical analysis
Data was retrieved from each relevant paper and
entered into a purpose-designed database using SPSS
11.0e for Windows. Data was aggregated and is
presented as means with ranges.Results
One hundred and thirty six papers were identified
with reference to the BBAVF. Twelve were written in
languages other than English and were, therefore,
excluded and of the remainder only 28 were regarded
as directly relevant to this review. Of these 28 studies,
four were prospective (one randomised, three non-
randomised) and 24 were retrospective from which
reliable data regarding primary and/or secondary
patency rates and complications could be retrieved.Surgical technique of formation of the BBAVF
The original description by Dagher in 1976 described
surgery on an out-patient basis under local anaes-
thesia.8,9 Through three incisions the basilic vein was
mobilised, relocated through a subcutaneous tunnel
and anastomosed end-to-side with the brachial artery.
Two weeks was allowed for the fistula to mature
before instigating haemodialysis. LoGerfo et al. used a
similar but modified technique using two incisions
also adopted later by Dagher.10,11 Davis described a
similar technique using one long incision in which the
fistula was laid subcutaneously rather than being
tunnelled.12,13 More recently there have been reports
of minimally invasive techniques including video
assisted transposition.14 These techniques may avoid
a long wound incision in the arm and may reduce pain
but have yet to gain popularity.
One stage vs. two-stage procedure
Many surgeons now perform the technique as a two-
stage procedure. El Mallah randomised 40 patients to a
one-stage or a two-stage procedure: Primary patency
rates were 50 and 80%, respectively, at a median
follow-up of 15 months.15 A retrospective study of 40
patients by Hossny showed no significant difference in
12 months secondary patency rates between one and
two-stage procedures at 90 and 84%, respectively.16
The former study would indicate a benefit for the two-
stage procedure although larger randomised trials
may answer this question more reliably. The staged
procedure may give the vein time to arterialise and
strengthen in order to withstand superficialisationEur J Vasc Endovasc Surg Vol 31, 1 2006
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occlusion rates in the one-stage procedure may reflect
the damage that can be caused by extensive dissection
of this thin walled vein. Most authors now agree that
the fistula should be left for 4–6 weeks to mature
before use so as to prevent complications such as
thrombosis.Fig. 2. Basilic vein elevation—the vein has been elevated
from its anatomically deep position to lie directly beneath
the incision.Superficialisation—transposition vs. elevation
Different surgical techniques and their relation to
fistula patency have been investigated in only one
retrospective study.16 Seventy BBAVFs were con-
structed, transposed in 30 patients and elevated in 40
patients (20 in one-stage and 20 in two-stages).
Cumulative secondary patency rates at 1 year were
87, 90 and 84% in the transposed, elevated in one-stage
and elevated in two-stage groups, respectively. At 2
years, these figures were 83, 70 and 68%, respectively.
The total complication rate was significantly higher in
the elevated group (71.4 vs. 28.6%) and the transposed
vein was also more favoured by dialysis staff. These
results would indicate that transposition may be better
but again larger randomised trials would allow more
reliable conclusions to be drawn. Figs. 1–3 show the
techniques of elevation and transposition.Primary patency rates of the BBAVF compared
with other fistulas
The general patency rates of radial-cephalic, brachial-
cephalic and prosthetic fistulas are shown in Table 1.
When the primary patency rate of the BBAVF is
compared with other fistulas it appears to be a reliable
fistula. The radial-cephalic fistula which is routinely
used as a primary fistula because of its good long-termFig. 1. Basilic vein mobilisation (the second stage of a two-
stage procedure). The medial cutaneous nerve of the forearm
is seen traversing the vein.
Eur J Vasc Endovasc Surg Vol 31, 1 2006results has reported 1 year primary patency rates of
70–91% although a recent meta-analysis suggests that
the rate may actually be as low as 62.5%.5,17,18
One of the most commonly performed alternative
fistulas is the prosthetic PTFE graft with 1 year
primary patency rates ranging from 62 to 87%.19–21
Coburn and Carney reported results of a comparison
between PTFE and the BBAVF.21 The primary patency
rate of the BBAVF (90%) was superior to that of PTFE
(70%) at 1 year and at 2 years (86 vs. 49%).
Complications were two and a half times more
frequent in the PTFE group (17 vs. 43%). They
concluded that the PTFE graft does have some
advantages over the BBAVF in that it is technically
easier to perform, has high dialysis flow rates and can
be punctured sooner, but wherever possible the
BBAVF is to be preferred based on patency and
lower rates of complications. In a retrospective paperFig. 3. Basilic vein transposition—the vein has been super-
ficialised and tunnelled to lie away from the incision.
Table 1. Primary patency rates of different types of arterio-venous
fistula
Fistula type Author (year) 1 year primary
patency (%)
Radial-cephalic Foran (1975) 91
Kinnaert (1977) 90
Rooijens (2004) 62.5
Brachial-cephalic Dunlop (1986) 70
Nazzal (1990) 75
Bender (1995) 84
PTFE graft Tellis (1979) 62
Anderson (1980) 87
Coburn (1994) 70
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PTFE fistulas.22 PTFE grafts had a significantly higher
thrombosis rate (51 vs. 30%) and a higher infection rate
(10 vs. 0%). Dialysis related complications (haemor-
rhage and haematoma) were higher in the BBAVF
group (20 vs. 5%). Two year primary patency rates for
the BBAVF were 70 vs. 46% for PTFE.
Gormus et al. reported slightly better short term
primary patency rates in radial-basilic fistulas created
in the forearm when compared with BBAVFs created
at the elbow (90 vs. 80%, respectively, at 10 months) but
with more complications.23 Primary patency rates of
the brachial-cephalic fistula have been reported at 70–
84%.24–26 This fistula is also not without problems. In a
study by Dunlop et al. 81 fistulas were performed in 77
patients.24 Overall patency was 70% at 1 year, 57% at 2
years and 50% at 3 years. Cardiac failure and steal
syndrome were significant problems with the side to
side anastomosis and two patients died from fistula
complications (haemorrhage and high output cardiac
failure).
Certain patient characteristics are associated with
poorer outcome. Many are diabetic although several
studies have failed to show that this group have a
worse fistula outcome.27 The same authors have
reported primary access failure to be higher in females
than in males. Several studies have shown older age to
be a significant factor in access failure, as well as
obesity, previous vascular access and ipsilateral
central venous catheterisation.27–29 Many patients
have numerous comorbidities including diabetes and
cardiovascular disease making access difficult and
making them prone to complications including death.
Table 2 reports the studies that have assessed the
BBAVF from 1976 to the present day.8,10–12,15,16,21,22,27,
29,30–47 Many of the early studies failed to distinguish
between primary and secondary patency rates and
failed to provide data regarding patient demo-
graphics. Overall, the mean (range) primary patency
rate of the BBAVF at 12 months follow-up from the
studies listed in Table 2 that specifically reporta primary patency rate, is 72% (35–92) out of 890
fistulas. The mean (range) primary patency rate of the
BBAVF at 24 months follow-up from the studies listed
in Table 2 that specifically report a primary patency
rate, is 60.4% (28–86) out of 580 fistulas.Secondary patency rates of the BBAVF
From most of the papers cited in this review,
secondary patency rates are only quoted in papers
from 1993 onwards. Overall, the mean (range)
secondary patency rate of the BBAVF at 12 months
follow-up from the studies listed in Table 2 that
specifically report a secondary patency rate, is 74.6%
(55–96) out of 807 fistulas. The mean (range) secondary
patency rate of the BBAVF at 24 months follow-up
from the studies listed in Table 2 that specifically
report a secondary patency rate, is 67.5% (52–86) out of
686 fistulas.Complications of the BBAVF
Fistula surgery is complex surgery and this group of
patients often have other co-morbidities in particular
diabetes, hypertension and coronary artery disease.
All fistula techniques have recognised complications
and the BBAVF is no exception.
Inability to create the fistula
An inability to perform the procedure at the time of
exploration due to an inadequate basilic vein (too
small, too short, already thrombosed or absent) is
reported to occur in 5–7% of cases.21,36,42
Failure of the fistula to develop
Failure to mature is an inability to use the fistula for
haemodialysis at 6 weeks.5 In a recent study by Rao
et al., failure of maturation was reported to be as high
as 38% although most other authors have not reported
rates as high as this.47 Logistic regression analysis
showed that age over 60 years was associated with
failure to mature and lower patency rates.
In a study by Hakaim et al. in 1998, the outcome of
radial-cephalic, brachial-cephalic and BBAVFs were
compared in patients with diabetes.40 Although not
randomised, the maturation rate of radial-cephalic
fistulas was only 30% compared with 100% for
BBAVFs and primary patency rates at 18 months
were 33 and 79%, respectively. They concluded that
in patients with renal failure and diabetes, a BBAVF
(or a brachial-cephalic fistula) are optimal fistulas for
primary access, not just as secondary access
procedures.Eur J Vasc Endovasc Surg Vol 31, 1 2006
Table 2. Patency rates and complications of the brachial-basilic arterio-venous fistula
Author (year) Type of study N Age (years) Male Follow-up
(months)
Primary
patency
Secondary
patency
Dagher (1976) Retrospective 24 44 (18–73) 13/23 8 (2–15) 92% –
LoGerfo (1978) Retrospective 25 – – 12 (0–19) 85% –
Barnett (1979) Prospective 16 (24–83) – (0–9) 94% –
Non-randomised
Dagher (1980) Retrospective 90 16–73 36/81 12 (0–60) 78% –
Cantelmo (1982) Retrospective 68 – – 12 70% –
24 66% –
36 57.2% –
Koontz (1983) Retrospective 12 – – 12 (1–34) 75% –
Dagher (1986) Retrospective 96 – – – 70% –
Davis (1986) Retrospective 66 – – ? (0–24) 83.3% –
Hibberd (1991) Prospective 15 54 (43–67) 1/15 12 70% –
Non-randomised 24 50% –
Hatjibaloglou (1992) Retrospective 25 (32–69) 4/22 12 (7–24) 81% –
Rivers (1993) Retrospective 65 (10–77) 25/65 12 – 55%
30 – 49%
Elcheroth (1994) Retrospective 80 (17–87) – 12 76.7% –
48 49.2
Coburn (1994) Retrospective 59 64 30/59 12 90% 90%
24 86% 86%
Stonebridge (1995) Retrospective 19 54 (28–73) – 16 (4–41) 79% –
El Mallah (1998) Prospective 40 35 23/40 15 (6–24) 50% 1S –
Randomised 80% 2S –
Butterworth (1998) Retrospective 23 60 (32–77) 10/30 8 (2–18) 78.3%
Hakaim (1998) Retrospective 26 59 (35–85) 16/26 18 79% –
Matsuura (1998) Retrospective 30 59 14/30 24 70% 70%
Humphries (1999) Retrospective 67 (11–73) 33/66 12 84% –
36 73% –
60 73% –
120 52% –
Murphy (2000) Retrospective 74 61 (24–94) 29/65 12 – 73%
24 – 53%
36 – 43%
Gibson (2001) Retrospective 181 66 96/181 12 44% 68%
24 28% 60%
Dahduli (2002) Retrospective 16 (25–85) – 6 85% –
Murphy (2002) Retrospective 74 60 (14–94) – 12 68% 75%
24 54% 60%
36 44% 46%
Tsai (2002) Prospective 54 61 (31–80) 23/54 12 90% 96%
24 73% 85%
36 65% 77%
Hossny (2003) Retrospective 70 49 (16–98) 27/70 26 (4–36)
30 TD 12 – 87%
24 – 83%
20 1SE 12 – 90%
24 – 70%
20 2SE 12 – 84%
24 – 68%
Segal (2003) Retrospective 99 55 46/99 12 47% 64%
24 41% 58%
Taghizadeh (2003) Retrospective 75 49 (6–77) – 12 92% 66%
24 – 52%
36 – 43%
Rao (2004) Retrospective 56 56 30/56 12 35% 47%
TD, transposed; 1SE, one-stage elevation; 2SE, two-stage elevation; –, not stated.
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The incision for this procedure is longer than for many
other access procedures. Post-operative analgesia can
be facilitated by the introduction of long acting local
anaesthetic at the time of surgery. An epidural catheter
can be placed in the axillary sheath at the time ofEur J Vasc Endovasc Surg Vol 31, 1 2006surgery and boluses of local anaesthesia introduced
over several days.39 However, this necessitates an in
hospital stay of several days whereas most patients are
now treated and discharged within 24 h. Most authors
do not specifically report pain indicating that it is
probably not a significant problem.
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Bleeding may present as a haematoma requiring no
intervention, haematoma requiring wound explora-
tion and evacuation, or fistula rupture. Of the studies
listed in Table 2 that reported their complication rates,
there are 45 cases of haematoma out of 1180 giving a
rate of 3.8%. In the same patients there were three
(0.25%) fistula ruptures. Early haematoma causing the
fistula to fail can be due to premature venepuncture
and most surgeons now give the fistula a period of
maturation of 6 weeks prior to its use. In the study by
Hossny, haematoma formation was the major predis-
posing factor for fistula failure.16 Fistula rupture is a
serious complication that can lead to death if not
quickly corrected.11,38 Nicholson and Polo advise the
use of suction drains in these wounds but there is no
randomised trial of their use to show a benefit.48
Infection
Infection of the wound or fistula was initially reported
as common.8,9 With improved aseptic precautions this
is now much less but has still been reported in many
studies.10,11,15,31,32,39 Infection can be associated with
vein rupture and loss of the fistula.36 Of the studies in
Table 2 that have reported complication rates, the rate
of infection in the wound or the fistula is reported at
3.6% (42/1180).There is no randomised trial that has
assessed rates of wound and fistula infection in
patients randomised to peri-operative antibiotic vs.
no antibiotic. In the study by Taghizadeh et al., local
infection rate was reported in 8% (6/75) requiring
fistula ligation in two patients.46 In a retrospective
comparison of PTFE and BBAVF, there was a much
higher infection rate in the PTFE group at 16.1 vs. 3.4%
and overall complications were two and a half times
more frequent in the PTFE group.21
Stenosis
Stenosis is another commonly described complication
which can lead to subsequent thrombosis.8,32,34,36,39,46
Previously this required re-operation and reformation
of the fistula, interposition grafting or vein patch
angioplasty but with the advent of endovascular
techniques, many stenoses can now be treated by
percutaneous transluminal balloon angioplasty
(PTA).36 Although endovascular treatment may be
preferable for several reasons there is no conclusive
evidence that it results in better patency than surgical
treatment and indeed there is some evidence to the
contrary. Angioplasty can be cumbersome and result
in vein rupture. In a study by Marston et al. in which
115 patients with thrombosed dialysis shunts were
randomised to either surgical or endovascular treat-
ment, neither resulted in long-term function forthe majority of shunts but surgical management
resulted in significantly longer primary patency.48
Stenosis may be caused by poor surgical technique,
by an anastomosis that is too small to maintain the
necessary flow volume and velocity, angulation of the
vein and repeated venepuncture. Multiple stenoses
may occur late at a site of multiple venepuncture so
puncture should be performed in different areas of the
fistula.39 Of the studies listed in Table 2 that reported
their complication rates, there are 27 cases of stenosis
out of 1180 giving a rate of 2.3%.
Whether or not duplex monitoring is beneficial to
identify stenosis and instigate the use of PTA is as yet
undecided. Recent evidence albeit from prosthetic
grafts suggests that monitoring does not accurately
predict graft thrombosis or failure, nor does it prolong
graft life or reduce the cost of access related care.49
Thrombosis
Early thrombosis suggests a technical error with the
formation of the fistula and should lead to re-
exploration with angiography to identify anastomotic
and venous stenoses, kinking or twisting of the vein.50
Thrombus can sometimes be recovered by catheter
thrombectomy.9,50 This may be prevented by exact
surgical technique and the intra-operative adminis-
tration of intravenous heparin but to date there is no
randomised trial comparing the rates of early
thrombosis with the use of heparin. Late thrombosis
appears to be common in fistulas after several years
particularly in those that are not used for dialysis and
nearly all studies report episodes of fistula thrombosis.
In the study by Hossny, the rate of thrombosis was
reported to be 16.7%.16 Taghizadeh et al. reported a
thrombosis rate as high as 33% and Murphy et al.
reported a rate of 22%.42,46 Of the studies listed in
Table 2 that reported their complication rates, there are
114 cases of thrombosis out of 1180 giving a rate of
9.7%.
Turmel-Rodrigues et al. reported a large series of
long term results of the treatment of thrombosis and
stenosis in fistulas and prosthetic grafts.51 This
included dilations, stenting and declotting procedures
in 449 arterio-venous fistulas of which 74 were upper
arm fistulas. Initial success ranged from 78 to 98%.
They concluded that percutaneous treatment of
thrombosis and stenosis achieves good patency rates
but that prosthetic grafts had a much poorer outcome.
Distal embolisation
Embolisation is an uncommonly-reported event.
Dagher described one case in which embolisation to
the fingers occurred although the patient died of
unrelated causes prior to revision of the fistulaEur J Vasc Endovasc Surg Vol 31, 1 2006
F. P. Dix et al.76and the paper does not indicate at what time point this
occurred.11
High output cardiac failure
High output cardiac failure is uncommon but associ-
ated with a high mortality and many papers specifi-
cally comment on the absence of this complication
which appears to be more common with the side-to-
side brachial-cephalic fistula.9,10,31,35,39 The diagnosis
often remains unrecognised for long periods. Murphy
et al. reported one late case out of 74 fistulas and this
resolved after spontaneous thrombosis of the fistula.42
Engelberts et al. described one case causing life-
threatening heart failure caused by excessive shunting
of blood through the fistula demonstrated by invasive
measurement of cardiac output, systemic arterial
blood pressure, systemic vascular resistance and
oxygen consumption before and after temporary
occlusion of the fistula.52 The patient recovered after
surgical closure of the fistula. None of the papers in
Table 2 report a case of high output cardiac failure
although there was one case of cardiac arrest and one
myocardial infarction in the study by Rao et al.47 In a
recent study by Nakhoul et al., a high prevalence of
pulmonary hypertension was found in patients with
ESRD on chronic haemodialysis via an AVF.53 They
measured endothelin-1 and nitric oxide levels and
pulmonary artery Doppler pressures in 42 patients
before and after haemodialysis. Patients with pulmon-
ary hypertension had higher cardiac outputs, higher
endothelin-1 levels and greater rises in nitric oxide
metabolites. Pulmonary artery pressure and cardiac
output appeared to transiently decrease after tempor-
ary occlusion of the fistula and permanently decrease
after successful transplantation. They concluded that
haemodialysis-induced nitric oxide production in
patients with pulmonary hypertension contributes to
increased pulmonary vascular tone. Temporary or
permanent shunt closure was associated with restor-
ation of pressure and cardiac output indicating that
excessive pulmonary blood flow is involved in
pulmonary hypertension in these patients. The inci-
dence of high output cardiac failure is probably less
than 0.2% (2/1180) based on the available figures in
Table 2.
Steal syndrome
Steal syndrome is an important and recognised
complication of fistula formation although it is
uncommon.11,21,32,34–36,38,39,41,46 If the anastomosis is
too large, arterial blood is ‘stolen’ from the distal
arteries to the hand as blood preferentially flows from
the brachial artery to the basilic vein. It is imperative,
therefore, to create an anastomosis that is not too smallEur J Vasc Endovasc Surg Vol 31, 1 2006so as to cause thrombosis and not too large so as to
cause steal—most authors recommend an anastomosis
of only 5–7 mm in length. The arteriotomy for
anastomosis in this procedure is smaller than that
used for a PTFE anastomosis (less flow is required in
autogeneous material to maintain patency). As a result
steal syndrome is less common and high output
cardiac failure is less likely to occur.54
Steal syndrome usually presents with coldness of
the fingers, occasionally with true ischaemia and
sometimes only occurs on exertion of the limb.
Although in most cases it presents in the immediate
post-operative period, in some papers it has been
reported late even after 10 years presumably due to
expansion of the fistula over time. Occasionally the
steal may resolve spontaneously within a few days.36
In some case steal requires ligation of the fistula.34,39,41
Berman et al. reported success in limb salvage whilst
maintaining a functioning fistula using a distal
revascularisation-interval ligation technique.55 They
claim that the technique restores antegrade flow,
eliminates the pathway for the steal physiologic
mechanism and maintains continuous dialysis. Papa-
savas et al. reported the rate of symptomatic steal (not
all were brachial-basilic fistulas) to be 17% with a half
of these needing revision of the fistula.56 They
recommend that by measuring the digital-brachial
pressure index (DBI), a DBI!0.6 on the day of surgery
can predict which patients are at risk of symptomatic
steal. Odland et al. reported a rate of 6.4% and also
recommended the use of DBI using intraoperative
photoplethysmography.57 Rao et al. reported a rate of
5.4% (3/56), two requiring distal revascularisation or
interval ligation and one requiring partial finger
amputation.47 Levine described three cases in which
hand amputation was required for severe ischemia
following access surgery.58 Risk factors for this
included peripheral vascular disease, diabetes, mul-
tiple interventions and the use of a synthetic graft. Of
the studies listed in Table 2 that reported their
complication rates, there are 34 cases of steal out of
1180 giving a rate of 2.9%.Ischaemic neuropathy
This is a rare complication of brachial artery fistula
thought to be due to nerve ischaemia or infarction.59
Often predisposed by diabetes, the patient complains
of profound weakness and severe pain and para-
sthesiae postoperatively in the distribution of the
median, ulnar or radial nerves.50 Although there is no
evidence of distal arterial insufficiency, the treatment is
prompt ligation of the fistula.
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Pseudoaneurysm formation is reported in several
studies and usually occurs at a site of repeated
venepuncture hence most dialysis technicians and
patients are taught to alter the site of access on each
occasion.10,11,15,21,22,31,34–36 True aneurysm formation
can also occur at the arterio-venous anastomosis. The
rate of aneurysm formation is, however, much less
than that reported with PTFE grafts.21 Of the studies
listed in Table 2 that reported their complication rates,
there are 22 cases of pseudoaneurysm out of 1180
giving a rate of 1.9%.
Oedema of the forearm and hand
Transient oedema of the hand and forearm is common
but under-reported. In most cases it resolves with arm
elevation in a sling without any long term conse-
quences.30 Murphy et al. reported the incidence to be
approximately 24% and Hossny reported a rate of 21%
but others have reported the rate to be zero.9,16,42 In
some cases it is associated with wound infection.12,35
Occasionally the oedema has been severe enough to
warrant ligation of the fistula.38,41 Severe arm oedema
should raise the possibility of an unrecognised
subclavian vein stenosis.37 Of the studies listed in
Table 2 that reported their complication rates, there are
44 cases of arm oedema out of 1180 giving a rate of
3.7% but this may be under-reported.
Other complications
Peripheral nerve compression has been reported by
Reinstein et al.60 They presented three cases: one radial
nerve compression by a basilic vein haematoma, one
median nerve compression secondary to a graft
associated abscess and one median nerve compression
secondary to a basilic vein aneurysm. Surgical
decompression led to full nerve recovery in all. The
authors do not however indicate how many patients
had undergone this fistula formation, so we are unable
to draw conclusions as to the incidence of this
complication although it would seem to be rare.
Carpal tunnel syndrome is reported to be common
in the forearm AVF making the upper arm a more
suitable place for fistula formation as long as care is
taken to identify and preserve the relevant nerves.61
Median nerve compression has also been reported by
Barnett et al.30 Cutaneous nerve dysfunction has also
been reported.34
Other uncommon complications include lymphatic
leak.16,39,45 Of the studies listed in Table 2 that reported
their complication rates, there are six cases of
lymphatic leak out of 1180 giving a rate of 0.5%.
Subclavian vein occlusion has been reported in one
case in Table 2.39 Segal et al. reported one case of flapnecrosis and three cases of wound dehiscence in the
same series of patients.29Discussion
We have seen from the available literature reviewed
here, that the BBAVF has primary patency rates and
secondary patency rates of 72 and 60%, respectively, at
1 year. These patency rates are comparable to those of
the brachial-cephalic fistula but better than a recent
meta-analysis of radial-cephalic patency and better
than patency for prosthetic grafts.5,21 Also, infection
rates are much lower for the BBAVF than for the
prosthetic loop graft.21 Prosthetic graft infection is
reportedly high at 19% necessitating removal of the
graft.62 These grafts are also associated with more steal
symptoms, high output cardiac failure, aneurysm
formation, thrombosis, deterioration in function over
time and pseudoluminal cannulation.63,64
The current DOQI guidelines suggest that the order
of preference for the formation of AVFs should be a
radial-cephalic AVF, followed by a brachial-cephalic
AVF, followed by a prosthetic loop graft, followed by a
BBAVF. In the light of the data reviewed here, this
order would seem illogical for the reasons listed
above. On the basis of this data it would seem more
prudent to attempt a BBAVF before attempting a
prosthetic loop graft in the majority of patients
needing secondary access procedures.
As a secondary access procedure there are several
advantages of the BBAVF over other forms of fistula.
Advantages for the patient and the dialysis technician
are that it provides a large, long, straight conduit for
dialysis. When elevated or transposed to a superficial
position it is easy to puncture (particularly useful for
patients on home dialysis), resilient to repeated
puncture, there is low risk of nerve injury caused by
puncture and the position of the fistula is obvious by
the position of the arm incision. Post-dialysis bleeding
is reportedly easy to stop by direct pressure, which is
not always the case with prosthetic grafts. The
available evidence suggests that a two-stage pro-
cedure and transposition rather than elevation may
be associated with better outcomes although more
studies are required. There do not appear to be many
disadvantages in using the BBAVF over other forms of
fistula except perhaps that it requires two separate
operations although both can be done under local
anaesthetic.
The limitations of the present review are that there
are few randomised trials from which to draw
conclusions and for this reason, this paper is presented
as a review rather than a meta-analysis. It is clear thatEur J Vasc Endovasc Surg Vol 31, 1 2006
F. P. Dix et al.78in order to answer some of the questions raised by
access surgery, there is a need for well conducted
randomised trials although many of the procedures
used are likely to remain in use by personal preference
rather than based on scientific evidence.Conclusions
No one form of fistula access surgery is without
problems and surgery should, therefore, be tailored to
the needs of the patient, the availability of suitable
veins for access and the ability of the operating
surgeon (most access surgery is in some way
centralised to surgeons with an interest in this field).
From the available evidence and despite the current
DOQI guidelines, for secondary access procedures, the
majority of patients will be best treated by a
transposed basilic vein fistula which has good long-
term patency rates and relatively few complications
when compared with other types of fistula.References
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